Science and Research

ARTEMIDE Lung 04 (D702GC00001): A Global Phase III Study of Rilvegostomig or Pembroli-zumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Can-cer (ARTEMIDELung04)

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Study details
Study-ID: NCT06868277, 2024-517780-24-00
Study-ID: NCT06868277, 2024-517780-24-00
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: TLRC
DZL Participating Sites: TLRC
Start Date: 10.04.2025
Completion Date: 02.12.2030
Status: Recruiting
Status: Recruiting
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.